MariMed Q2 Adj. EPS $(0.01), Inline, Sales $41.925M Beat $39.800M Estimate
MariMed (OTC:MRMD) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The company reported quarterly sales of $41.925 million which beat the analyst consensus estimate of $39.800
MariMed sold more stuff than people expected this quarter, which is a good sign. When a company beats its sales target, it means the business is growing stronger than forecasters thought.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.